title: What is the contribution of protease inhibitors to the high mortality of patients with cirrhosis receiving HCV treatment?
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rio Grande do Sul, Brazil; Hospital Nossa Senhora da Conceição (HNSC), Rio Grande do Sul, Brazil.
authors.forename: Cristiane V
authors.initials: CV
authors.lastname: Tovo
authors.affiliation: Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rio Grande do Sul, Brazil.
authors.forename: Angelo A
authors.initials: AA
authors.lastname: Mattos
authors.affiliation: Hospital Nossa Senhora da Conceição (HNSC), Rio Grande do Sul, Brazil.
authors.forename: Paulo R L
authors.initials: PR
authors.lastname: Almeida
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D011392:Proline